Pivotal Therapeutics appoints pharmaceutical executive James Connolly to Board of Directors

Pivotal Therapeutics appoints pharmaceutical executive James Connolly to Board
                                 of Directors

PR Newswire

WOODBRIDGE, ON, March 10, 2014

WOODBRIDGE, ON,  March  10,  2014 /PRNewswire/  -  Pivotal  Therapeutics  Inc. 
(OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus  on 
Omega-3  therapies  for  cardiovascular  disease  (CVD)  and  overall  health, 
announced today that James Connolly has been appointed to the Company's  Board 
of Directors,  effective immediately.  Mr. Connolly  brings over  27 years  of 
experience in the pharmaceutical  industry to Pivotal,  including 23 years  in 
various leadership positions at Wyeth, formerly American Home Products, a  $23 
billion pharmaceutical and health products company that was acquired by Pfizer
in 2009.

During his 23 years at  Wyeth, Jim served in a  series of leadership roles  of 
increasing responsibility  including  Executive  Vice  President  and  General 
Manager, Wyeth Vaccines, President, Wyeth  Canada, Vice President - Sales  and 
Marketing, Area  Business  Director,  Business Director  -  Wyeth/Medco  joint 
venture and Finance Director. Under Mr. Connolly's stewardship from 2005-2009,
Wyeth's vaccines business  grew from $800  million to over  $3 billion  driven 
principally with  the  creation  of  the  first  true  commercial  blockbuster 
vaccine, Prevnar. During Jim's  tenure leading Wyeth  Canada, sales more  than 
doubled to over $650  million in less  than four years,  and all key  promoted 
brands including Effexor  XR, Prevnar,  Enbrel, Alesse,  Premarin and  BeneFix 
achieved the #1 market share position in each of their respective categories.

"We are very  pleased to  welcome Jim  to the  Board of  Directors of  Pivotal 
Therapeutics," said Dr. George Jackowski, Co-founder and Chairman of Pivotal's
Board of  Directors.  "Jim's  wealth of  experience  in  brand  establishment, 
commercialization and growing sales will be invaluable as the Company  expands 
its commercialization team to execute the  broader launch of its Medical  Food 

"I am excited to be joining Pivotal's board of directors and working with  the 
company to help strengthen the overall commercialization efforts," stated  Mr. 
Connolly. "Treating an Omega-3 deficiency with an innovative Medical Food such
as VASCAZEN^®  is a  unique approach  to this  large market  and represents  a 
significant opportunity."

Mr. Connolly  currently serves  as an  advisor at  Crossover Healthcare  Fund, 
director of Vaxess Technologies and a director at Aeras, a non-profit  biotech 
organization  developing  vaccines  for   tuberculosis  and  other   neglected 
diseases, where he  formerly served  as CEO  until 2013.  He holds  a B.S.  in 
Business Administration from Washington University, St. Louis, MO.

About Pivotal Therapeutics Inc.

Pivotal Therapeutics is a publicly traded (OTCQX: PVTTF) (CSE: PVO)  specialty 
pharmaceutical company  with a  focus on  cardiovascular disease  and  overall 
health. Pivotal Therapeutics' lead product  VASCAZEN^® is a prescription  only 
Medical Food  formulated  to  meet  the dietary  Omega-3  deficient  needs  of 
patients with cardiovascular disease  through elevating Eicosapentaenoic  acid 
(EPA) and Docosahexaenoic acid (DHA) to levels associated with reduced risk of
cardiovascular complications.  OMAZEN^®  is  a  pharmaceutical  grade  Omega-3 
providing over 90% pure  Omega-3 in each capsule  for the maintenance of  good 
health. OMAZEN^® is a patented product available for sale and distribution  in 


VASCAZEN^® is currently available in the  U.S. as a prescription only  Medical 
Food  specifically  formulated  for  the  dietary  management  of  an  Omega-3 
deficiency in cardiovascular patients. VASCAZEN^® is a >90% pure Omega-3  with 
a proprietary 6:1  EPA:DHA fatty acid  formulation, protected by  a series  of 
both U.S. and foreign patents. VASCAZEN^® has been clinically shown to correct
an  Omega-3  deficiency  within  eight   weeks  of  treatment  with   positive 
concomitant  effects  on  the  lipid  profiles,  mainly  a  48%  reduction  of 
triglycerides and an  increase of  HDL without  negative impact  on the  LDL-C 
lipid profile. VASCAZEN^®'s results were achieved  with a dose of 3 grams  of 
EPA and DHA per day of a prescription grade, high purity Omega-3.

Disclosure Notice
The information contained in this document is as of March 10, 2014. This press
release contains forward-looking  statements. Such forward-looking  statements 
are subject to  a number of  risks, assumptions and  uncertainties that  could 
cause Pivotal's actual results  to differ materially  from those projected  in 
such forward-looking statements. These statements can be identified by the use
of words  such  as  "will",  "anticipate",  "estimate",  "expect",  "project", 
"forecast", "intend", "plan", "believe",  "project", "potential", and  similar 
expressions with any discussion of  future operating or financial  performance 
or events. In particular,  factors that could cause  actual results to  differ 
materially from those  in forward  looking statements  include the  following: 
Pivotal's inability to obtain additional financing on acceptable terms; growth
in costs and expenses; inability to compete with others who provide comparable
products; risk that  the Company's  products will not  gain widespread  market 
acceptance; risks  relating  to the  Company's  ability to  maintain  its  CSE 
listing. Forward-looking statements speak only as of the date made and are not
guarantees of  future performance.  The Company  undertakes no  obligation  to 
publicly update or  revise any  forward-looking statements  contained in  this 
document as a result of new information or future events or developments.  CSE 
has not  reviewed and  does  not accept  responsibility  for the  adequacy  or 
accuracy of this information.

SOURCE Pivotal Therapeutics Inc.


Company Contacts:

Rachelle MacSweeney
President and Chief Operating Officer
Phone: 905-856-9797

Kristine DiMatteo
Communications and Public Relations Manager
Phone: 905-856-9797 ext. 231

Press spacebar to pause and continue. Press esc to stop.